twoXAR To Present Data From In Vivo Studies Investigating New Rheumatoid Arthritis Drug Candidates At IMMUNOLOGY 2017

PALO ALTO, Calif.--(BUSINESS WIRE)--twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced that the company will present key data on its in vivo-validated rheumatoid arthritis (RA) drug candidates at IMMUNOLOGY 2017, the annual meeting of the American Association of Immunologists, taking place May 12 – 16 in Washington, D.C.

“We are looking forward to presenting these promising results at the world’s largest gathering of immunologists. Utilizing our AI-driven drug discovery platform, we have identified candidates that we believe could expand treatment options for RA by targeting novel mechanisms of action”

“We are looking forward to presenting these promising results at the world’s largest gathering of immunologists. Utilizing our AI-driven drug discovery platform, we have identified candidates that we believe could expand treatment options for RA by targeting novel mechanisms of action,” said Andrew A. Radin, co-founder and Chief Executive Officer of twoXAR.

Each of the candidates were identified using twoXAR’s computational drug discovery platform which rapidly performs unbiased analyses of biological, chemical, and clinical data to predict and rank potentially efficacious drugs. twoXAR computationally screened a library of more than 22,000 potential drug candidates and the 10 novel candidates with the strongest evidence for potential efficacy and safety were selected for these studies. Candidates were then screened in vivo in a collagen-induced arthritis model of RA. Therapeutic treatment with three candidates significantly reduced ankle size, alleviated limb inflammation, improved joint histopathology, and reduced mobility impairments tracked by a novel digital motion endpoint. These candidates are currently approved for metabolic, allergic, and psychiatric indications, and do not act on common RA therapeutic targets.

The poster titled, “An Integrative Bioinformatics Approach Identifies In Vivo Validated Drug Candidates with Novel Mechanisms of Action in Rheumatoid Arthritis¹,” will be presented on Saturday, May 13^th at 2:30pm ET. The abstract can be viewed online or found through the conference website at: www.immunology2017.org.

About twoXAR

twoXAR is an artificial intelligence-driven biopharmaceutical company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry partnerships. Based in Palo Alto, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science, and software development. For more information, please visit www.twoXAR.com.

¹ Daugherty AC, Farrington C, Hakim I, Radin AM, Noblin ES, Chua MS, Sirota M, Rabe M, Fernald G, Ford D, Schaevitz L, Radin AA. An Integrative Bioinformatics Approach Identifies In Vivo Validated Drug Candidates with Novel Mechanisms of Action in Rheumatoid Arthritis. Poster presented at IMMUNOLOGY 2017. The annual meeting of The American Association of Immunologists. May 13; Washington, D.C.